DALLAS, November 1, 2014 /PRNewswire/ --
RnRMarketResearch.com adds Gonorrhea and Toxoplasmosis market research reports on Pipeline Review, H2 2014 to its store. The reports provide an overview of the Gonorrhea and Toxoplasmosis therapeutic pipeline.
The report "Gonorrhea-Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Gonorrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gonorrhea and special features on late-stage and discontinued projects.
Gonorrhea is a common human sexually transmitted infection caused by the bacterium Neisseria gonorrhoeae. The usual symptoms in men are burning with urination and penile discharge. Women, on the other hand, are asymptomatic half the time or have vaginal discharge and pelvic pain. In both men and women, if gonorrhea is left untreated, it may spread locally, causing epididymitis or pelvic inflammatory disease or throughout the body, affecting joints and heart valves. Complete Report with Table of Content @http://www.rnrmarketresearch.com/gonorrhea-pipeline-review-h2-2014-market-report.html .
The common treatment is with ceftriaxone (Rocephin), as antibiotic resistance has developed to many previously used medications. This is typically given in combination with either azithromycin or doxycycline, as gonorrhea infections may occur along with chlamydia, an infection that ceftriaxone does not cover. Some strains of gonorrhea have begun showing resistance to this treatment, which will make infection more difficult to treat
Companies Involved in Gonorrhea Therapeutics Market Development discussed in this report include Melinta Therapeutics, Inc, Cubist Pharmaceuticals, Inc., PTC Therapeutics, Inc. and Genocea Biosciences, Inc. Gonorrhea - Drug Profiles discussed in this report cover Delafloxacin, Solithromycin, Gonorrhea Vaccine, PTC-672 and edodekin alfa SR. Order a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=235045 .
The report "Toxoplasmosis-Pipeline Review, H2 2014"provides comprehensive information on the therapeutic development for Toxoplasmosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Toxoplasmosis and special features on late-stage and discontinued projects.
Toxoplasmosis is a parasitic disease caused by the protozoan Toxoplasma gondii. The parasite infects most genera of warm-blooded animals, including humans, but the primary host is the felid (cat) family. Animals are infected by eating infected meat, by ingestion of feces of a cat that has itself recently been infected, and by transmission from mother to fetus. Cats are the primary source of infection to human hosts, although contact with raw meat, especially lamb, is a more significant source of human infections in some countries. Fecal contamination of hands is a significant risk factor. Complete Report with Table of Content @http://www.rnrmarketresearch.com/toxoplasmosis-pipeline-review-h2-2014-market-report.html .
During acute toxoplasmosis, symptoms are often influenza-like: swollen lymph nodes, or muscle aches and pains that last for a month or more. Rarely will a human with a fully functioning immune system develop severe symptoms following infection. Young children and immunocompromised people, such as those with HIV/AIDS, those taking certain types of chemotherapy, or those who have recently received an organ transplant, may develop severe toxoplasmosis. This can cause damage to the brain (encephalitis) or the eyes (necrotizing retinochoroiditis).[14] Infants infected via placental transmission may be born with either of these problems, or with nasal malformations, although these complications are rare in newborns. The toxoplasmic trophozoites causing acute toxoplasmosis are referred to as Tachyzoites, and are typically found in bodily fluids.
Snowdon Inc. is a company involved in Toxoplasmosis Therapeutics market development as well as
Drug Profiles like SND-226, toxoplasmosis vaccine (SAG1), toxoplasmosis vaccine, SNT-18 and Monoclonal Antibody for Toxoplasmosis are discussed in this research. Order a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=235046 .
Scope
- The report provides a snapshot of the global therapeutic landscape of Gonorrhea and Toxoplasmosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Gonorrhea and Toxoplasmosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Gonorrhea and Toxoplasmosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Gonorrhea and Toxoplasmosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Gonorrhea and Toxoplasmosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Gonorrhea and Toxoplasmosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Browse more reports on Therapeutics Market @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics .
About Us:
RnR Market Research is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers.
Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
sales@rnrmarketresearch.com
